What is the recommended algorithmic approach for an 83-year-old male with non‑small cell lung carcinoma and elevated thyroid‑stimulating hormone and high free thyroxine levels?

Algorithmic Approach for 83-Year-Old Male with NSCLC and Abnormal Thyroid Function

Your patient has a paradoxical thyroid profile (elevated TSH with elevated FT4) that requires immediate investigation before any cancer treatment decisions, as this pattern suggests either assay interference, non-thyroidal illness, or a pituitary/resistance disorder—not simple hypothyroidism or hyperthyroidism.

Step 1: Urgent Thyroid Workup (Within 48-72 Hours)

Repeat thyroid function tests on a different immunoassay platform to rule out assay interference or heterophilic antibodies, which are common causes of discordant TSH/FT4 results 1. The combination of TSH 9.36 mIU/L with FT4 60.48 pmol/L (elevated, assuming normal range ~12-22 pmol/L) is biochemically inconsistent with primary thyroid disease.

Specific tests to order:

• TSH and FT4 on alternative assay (different manufacturer)
• Total T3 to assess peripheral conversion
• Anti-TSH receptor antibodies and anti-thyroid peroxidase antibodies
• Comprehensive metabolic panel including liver and renal function
• Medication review for drugs affecting thyroid function (amiodarone, lithium, tyrosine kinase inhibitors if previously treated)

Three possible scenarios:

Scenario A: Laboratory artifact (most likely)

• If repeat shows normal TSH with normal FT4: proceed with NSCLC treatment algorithm
• Heterophilic antibodies or macro-TSH can falsely elevate TSH 2

Scenario B: Non-thyroidal illness syndrome

• Common in malignancy and elderly patients 3
• If confirmed: no thyroid treatment needed; proceed with cancer management

Scenario C: True thyroid dysfunction

• TSH-secreting pituitary adenoma (rare)
• Thyroid hormone resistance (very rare)
• Requires endocrinology consultation before cancer treatment

Step 2: NSCLC Management Algorithm (Once Thyroid Status Clarified)

A. Immediate Molecular Testing (Do Not Delay)

Order comprehensive molecular profiling including 4:

• EGFR mutations (exons 18-21)
• ALK translocation
• ROS1 rearrangement
• BRAF V600E mutation
• PD-L1 expression (22C3 or SP263 assay)

B. Performance Status Assessment

Determine ECOG performance status:

• PS 0-1: Eligible for combination therapy
• PS 2: Consider carboplatin-based doublet or single-agent chemotherapy 5
• PS 3-4: Best supportive care only unless druggable mutation with minimal toxicity treatment 5

C. Treatment Algorithm Based on Molecular Results

If EGFR/ALK/ROS1/BRAF positive:

• First-line targeted therapy (osimertinib for EGFR, alectinib/brigatinib for ALK) 4
• Age 83 is NOT a contraindication for targeted therapy 5

If molecular tests negative (wild-type):

For PS 0-1 patients:

• If PD-L1 ≥50%: Pembrolizumab monotherapy [I, A] 4
• If PD-L1 1-49%: Pembrolizumab/pemetrexed/platinum (4 cycles) followed by pembrolizumab/pemetrexed maintenance [I, A] 4
• If PD-L1 <1%: Carboplatin-based chemotherapy doublet (carboplatin/pemetrexed for non-squamous, carboplatin/paclitaxel for squamous) 4

For PS 2 patients (age 83):

• Carboplatin-based doublet if adequate organ function [I, A] 5
• Single-agent chemotherapy (gemcitabine, vinorelbine, or pemetrexed for non-squamous) if not fit for doublet [I, B] 5

D. Elderly-Specific Considerations for Your 83-Year-Old

Perform geriatric assessment 6:

• Activities of daily living (ADLs)
• Instrumental ADLs
• Comorbidity index
• Cognitive function (Mini-Mental State Exam)
• Nutritional status
• Social support

Dose adjustments for elderly 5, 6:

• Carboplatin preferred over cisplatin (better tolerability)
• Consider 4 cycles instead of 6 if responding
• Monitor closely for myelosuppression and renal function

Step 3: Thyroid Management During Cancer Treatment

If true hypothyroidism confirmed (TSH >10 mIU/L on repeat):

• Initiate levothyroxine 25-50 mcg daily (lower starting dose for elderly and cardiac risk) 2
• Target TSH 4-6 mIU/L initially (avoid aggressive suppression in 83-year-old) 2
• Recheck TSH every 6-8 weeks until stable

Critical caveat: Immunotherapy (pembrolizumab, atezolizumab, nivolumab) can cause immune-related thyroid dysfunction in 24-48% of patients 7. Monitor TSH every 6-12 weeks during immunotherapy. Thyroid dysfunction during immunotherapy is associated with improved progression-free survival 7, so its development may be a favorable prognostic sign.

Step 4: Monitoring Schedule

During active treatment:

• TSH/FT4: Every 6-12 weeks if on immunotherapy, every 3 months if on chemotherapy alone
• Tumor response: CT chest/abdomen after 2-3 cycles 8
• Toxicity assessment: Before each cycle

Common pitfall to avoid: Do not delay cancer treatment waiting for "perfect" thyroid control unless patient has severe symptomatic thyrotoxicosis. The cancer takes priority for mortality risk in this 83-year-old.

Key Decision Points Summary

1. First 72 hours: Repeat thyroid tests on different platform
2. Week 1: Molecular testing results guide treatment selection
3. Week 2-3: Initiate cancer treatment based on PS and molecular profile
4. Ongoing: Monitor thyroid function every 6-12 weeks, especially if on immunotherapy

The paradoxical thyroid results must be resolved first, but do not delay molecular testing or staging workup while awaiting thyroid clarification.